Historical Valuation
Immunitybio Inc (IBRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.63 is considered Undervalued compared with the five-year average of -7.77. The fair price of Immunitybio Inc (IBRX) is between 22.29 to 23.61 according to relative valuation methord. Compared to the current price of 2.24 USD , Immunitybio Inc is Undervalued By 89.95%.
Relative Value
Fair Zone
22.29-23.61
Current Price：2.24
89.95%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Immunitybio Inc (IBRX) has a current Price-to-Book (P/B) ratio of -3.79. Compared to its 3-year average P/B ratio of -4.01 , the current P/B ratio is approximately -5.47% higher. Relative to its 5-year average P/B ratio of -8.96, the current P/B ratio is about -57.63% higher. Immunitybio Inc (IBRX) has a Forward Free Cash Flow (FCF) yield of approximately -16.32%. Compared to its 3-year average FCF yield of -21.37%, the current FCF yield is approximately -23.63% lower. Relative to its 5-year average FCF yield of -18.11% , the current FCF yield is about -9.86% lower.
P/B
Median3y
-4.01
Median5y
-8.96
FCF Yield
Median3y
-21.37
Median5y
-18.11
Competitors Valuation Multiple
AI Analysis for IBRX
The average P/S ratio for IBRX competitors is 452.46, providing a benchmark for relative valuation. Immunitybio Inc Corp (IBRX.O) exhibits a P/S ratio of 11.63, which is -97.43% above the industry average. Given its robust revenue growth of 425.07%, this premium appears sustainable.
Performance Decomposition
AI Analysis for IBRX
1Y
3Y
5Y
Market capitalization of IBRX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IBRX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IBRX currently overvalued or undervalued?
Immunitybio Inc (IBRX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.63 is considered Undervalued compared with the five-year average of -7.77. The fair price of Immunitybio Inc (IBRX) is between 22.29 to 23.61 according to relative valuation methord. Compared to the current price of 2.24 USD , Immunitybio Inc is Undervalued By 89.95% .
What is Immunitybio Inc (IBRX) fair value?
IBRX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Immunitybio Inc (IBRX) is between 22.29 to 23.61 according to relative valuation methord.
How does IBRX's valuation metrics compare to the industry average?
The average P/S ratio for IBRX's competitors is 452.46, providing a benchmark for relative valuation. Immunitybio Inc Corp (IBRX) exhibits a P/S ratio of 11.63, which is -97.43% above the industry average. Given its robust revenue growth of 425.07%, this premium appears sustainable.
What is the current P/B ratio for Immunitybio Inc (IBRX) as of Jan 09 2026?
As of Jan 09 2026, Immunitybio Inc (IBRX) has a P/B ratio of -3.79. This indicates that the market values IBRX at -3.79 times its book value.
What is the current FCF Yield for Immunitybio Inc (IBRX) as of Jan 09 2026?
As of Jan 09 2026, Immunitybio Inc (IBRX) has a FCF Yield of -16.32%. This means that for every dollar of Immunitybio Inc’s market capitalization, the company generates -16.32 cents in free cash flow.
What is the current Forward P/E ratio for Immunitybio Inc (IBRX) as of Jan 09 2026?
As of Jan 09 2026, Immunitybio Inc (IBRX) has a Forward P/E ratio of -5.69. This means the market is willing to pay $-5.69 for every dollar of Immunitybio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Immunitybio Inc (IBRX) as of Jan 09 2026?
As of Jan 09 2026, Immunitybio Inc (IBRX) has a Forward P/S ratio of 11.63. This means the market is valuing IBRX at $11.63 for every dollar of expected revenue over the next 12 months.